Trial Supports Wider Use of Adalimumab in Uveitis

Image depicting uveitis, created with AI.

A UK clinical trial has shown that adalimumab protects sight in a far wider group of patients with non-infectious uveitis than previously recognised.

Findings published in eClinicalMedicine suggest eligibility criteria should be widened.

Uveitis is the inflammation of the uvea, which is the middle, pigmented layer of the eye containing the iris, ciliary body, and choroid. Non-infectious uveitis is a leading cause of blindness in high-income countries. Adalimumab is already used in the NHS for arthritis and some forms of ocular inflammation and is the only non-steroid treatment licensed in the UK for uveitis.

The ASTUTE trial, co-led by Oxford University Hospitals and Bristol NHS Foundation Trust, recruited patients at 18 UK hospitals. All received adalimumab for 16 weeks plus standard care. Responders were then randomised to continue the drug or placebo (double-blind).

At one year, 31.4% of those continuing adalimumab experienced relapse or needed further treatment, versus 59% on placebo. NICE guidance (2017) funds the drug only for a narrow set of patients; ~85% of those randomised in ASTUTE would not have met the criteria. In this “excluded” group, continued treatment reduced treatment-failure risk by 63%, with the same overall benefit.

Dr Srilakshmi Sharma, Consultant Medical Ophthalmologist at the Oxford Eye Hospital and co-chief investigator, said: “We set out to answer a question that patients have been asking us in clinic for years, which is whether this drug would help them if only they were allowed to have it. The answer is yes, for many of them. These are people who come to our clinics with their sight at risk, and who we currently have to tell that the funding rules do not cover them. We now have UK trial evidence, from NHS clinics and patients, that the rules are drawn in the wrong place.”

Side-effects were no more common with adalimumab than placebo. University of Oxford health economists estimated an extra annual cost of £662 per patient and £2320 per treatment failure avoided; a cheaper biosimilar was used.

Co-chief investigator Dr Andrew Dick (University of Bristol and UCL) said: “This trial was designed to be difficult to argue with. We treated everyone first, so we knew who responded, and only then did we randomise. That design let us show, cleanly, that stopping the drug in people who are doing well on it leads to relapse in most of them. The implication for practice is straightforward: when it works, it needs to be continued, and in many more patients than are currently eligible.”

Patients helped design the trial. It was supported by the Birdshot Uveitis Society and the NIHR Health Technology Assessment Programme and NIHR Biomedical Research Centres at Moorfields and Oxford. Annie Folkard (Birdshot Uveitis Society) noted that more than a hundred participants contributed over years and deserve an answer that could change access. The team has submitted the eligibility findings to NICE.

Source: Oxford University Health Service

Nearly Half of Deaths Among Adults with Down Syndrome are from Avoidable Causes

Photo by Nathan Anderson on Unsplash

Roughly 47% of deaths among adults with Down syndrome in England were from causes classed as avoidable, with epilepsy and pneumonia as the leading treatable causes, and COVID-19 the leading preventable cause, according to a new study led by researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.

Nearly half of deaths among adults with Down syndrome in England are from causes that could potentially have been prevented or treated, according to a new study led by researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.

Published in JAMA Network Open, the study analysed the deaths of 3381 adults with Down syndrome and 15 347 other adults with a learning disability, recorded between 2016 and 2023 by the LeDeR programme (Learning from Lives and Deaths – people with a learning disability and autistic people (LeDeR)). The researchers compared them with Office for National Statistics data on more than four million deaths in the general population.

The researchers classed 47% of deaths among adults with Down syndrome as avoidable, meaning they happened before the age of 75 and could have been prevented through public health measures or treated with timely healthcare. Among other adults with a learning disability, the figure was 45%. Most avoidable deaths among adults with Down syndrome were from treatable causes, which accounted for 29% of all deaths in the group, with epilepsy (8.6%) and pneumonia (6.0%) the most common. Deaths related to epilepsy were more frequent than in either comparison group. COVID-19 was the leading preventable cause, accounting for 9.9% of deaths.

We have shown that individuals with Down syndrome have high rates of avoidable deaths due to treatable conditions such as lung infections. This is concerning and requires action, including vaccination programmes for common infections such as flu, COVID-19 and pneumococcal bacteria. People with Down syndrome would also benefit from monitoring for the complications of Alzheimer’s disease, which was a common cause of death.

André Strydom, Professor of Intellectual Disabilities at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London

Adults with Down syndrome died at a median age of 59.5 years, compared with 63.8 for other adults with a learning disability and 81.9 for the general population. After accounting for other factors, having Down syndrome was associated with higher odds of an avoidable death than among other adults with a learning disability, and with dying younger from an avoidable cause.

Within the Down syndrome group, people from ethnic minority backgrounds had higher odds of an avoidable death, and those living in more deprived areas died from avoidable causes at a younger age. Asthma, diabetes and osteoporosis were also linked to higher odds of avoidable death.

The way a death is recorded determines whether it can be recognised as avoidable. Death certificates frequently list Down syndrome as the underlying cause, which obscures the condition that led to the death. By taking the next condition listed instead, we were able to classify these deaths according to their actual cause, rather than as an inevitable consequence of the syndrome. Without that step, a substantial avoidable burden remains undetected.

Lili Bokor, first author of the study and Research Assistant at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London

Dr Rory Sheehan, at the Institute of Psychiatry, Psychology & Neuroscience, said: “This study shows that people with Down syndrome may have different patterns of morbidity and mortality compared to other people with a learning disability. Data collected through LeDeR have helped us to understand these differences which should enable professionals and health services to adapt their approaches, identify issues earlier, and provide more targeted intervention and treatment.”

Avoidable Mortality in Adults With Down Syndrome or With Other Intellectual Disabilities (Bokor, Yu, Carter, Chauhan, Sheehan, Strydom) is published in JAMA Network Open. DOI: 10.1001/jamanetworkopen.2026.43229

Source: King’s College London

How a New Generation of Gauteng Vets is Reimagining the Vet Visit

Photo by Judy Beth Morris on Unsplash

New Stats SA data shows pets are part of nearly a quarter of South African households, as a University of Pretoria veterinary hospital marks the first year of its specialist cat care facility.

2026 – South Africa is home to an estimated 2 million household cats, according to Statistics South Africa’s 2025 General Household Survey. The survey found that nearly a quarter of South African households own pets.

Ahead of September, which is recognised internationally as Animal Pain Awareness Month, the figures come at a time of growing demand for high quality, innovative and accessible pet healthcare services, offering an opportunity to reflect on how South Africans care for their animals. For cat owners, that can be particularly important because illness and pain are not always easy to spot. Changes in appetite, grooming, movement, behaviour or routine can sometimes be the first signs that something is wrong.

The timing is significant for the University of Pretoria’s Onderstepoort Veterinary Academic Hospital, which is marking more than a year since opening its specialist cat care centre. The unit is Gauteng’s first and South Africa’s second Gold Status facility and has treated more than 2000 feline patients since opening.

Rethinking the vet visit

Anyone who has tried to get a cat into a carrier knows that getting to the vet can sometimes feel like an event in itself. Once there, unfamiliar sights, sounds, smells and handling can add to the stress. For some cats, that can make an examination more difficult for both the animal and the veterinary team.

The specialist facility was developed in partnership with pet food giant Royal Canin to address those challenges by designing the veterinary environment around the particular needs of cats. Gold Status is the highest level in the Cat Friendly Clinic programme. It recognizes clinics that meet defined standards covering clinical facilities, veterinary knowledge and skills, and cat-centred care.

The facility includes dedicated spaces and separate waiting and consultation rooms, with attention paid to factors such as sight, sound and smell. It also uses low stress handling and provides training for staff and students. The result is an approach that goes beyond creating a separate waiting area. The physical environment, handling techniques and clinical practices are considered together as part of the patient’s care.

A year of putting the approach into practice

Since opening, the specialist clinic has treated cats with a range of conditions. The wider hospital also has a dedicated intensive care unit for cats, an isolation ward for feline outpatients and a separate area for cats within the small animal clinic.

As a pioneering teaching hospital, it trains approximately 180 veterinary students and 38 veterinary nursing students each year, supported by 90 clinicians and 42 professional nurses. Students gain practical experience they can take into veterinary practices across South Africa.

Tricky patients

Cats can be remarkably good at hiding signs that they are unwell. A change in appetite, grooming, movement, behaviour or routine may be subtle, but it can also be an indication that something is wrong. Stress can add another layer to the challenge. A frightened or highly stressed cat may be more difficult for a veterinary team to examine, potentially making it harder to assess what is happening. A calmer environment and appropriate handling can give the veterinary team a better opportunity to examine the patient and provide appropriate care.

For owners, the aim is a veterinary visit that feels less daunting. For veterinary teams, it is about creating better conditions for assessment and treatment. For future vets, it is about learning how the environment and approach to care can affect the patient experience.

The bigger picture

The partnership between the University of Pretoria and Royal Canin brings together veterinary education, clinical practice and private sector support, demonstrating how collaboration can help strengthen veterinary expertise in South Africa.

The role of veterinary care extends well beyond the wellbeing of household pets. It is essential to the health and welfare of animals across our communities, from domestic pets and farm livestock to South Africa’s unique indigenous wildlife, while also supporting food safety, the agricultural economy and efforts to prevent diseases from passing from animals to humans.

What the experts say

“At Onderstepoort, we believe feline medicine begins with feline dignity,” said Dr Alfred Kgasi, Director of the Onderstepoort Veterinary Academic Hospital. “Our students learn that a calm cat is a diagnosable cat, and that respect for the patient transforms outcomes for the owner, the clinician and the animal.”

“Royal Canin has always believed that supporting veterinary professionals means investing in the environments where care happens,” said Frank Chadinha, General Manager for Royal Canin South Africa. “By partnering with the University of Pretoria to develop this Gold Cat Friendly facility, we are helping create better experiences for cats today while supporting the veterinarians who will care for South Africa’s pets for decades to come.”

TB Killed 53 000 People in SA Last Year, According to the WHO

In 2025, around 235 000 people in South Africa had TB, and about 53 000 lost their lives to the disease. Photo: Unsplash

By Marcus Low for Spotlight

The number of people falling ill with TB in South Africa is declining year-on-year, but the number of deaths due to the disease remains stubbornly high.

For An estimated 235 000 people in South Africa fell ill with tuberculosis (TB) in 2025, while around 53 000 died of the disease. This is according to the World Health Organization’s (WHO) latest TB estimates, published this week alongside its Global Tuberculosis Report 2026. You can see the WHO’s TB country profile for South Africa here.

There is a clear downward trend in the number of people falling ill with TB. According to the WHO, South Africa’s TB incidence rate has declined by 63% since 2015. By contrast, the absolute number of annual deaths due to TB have declined by only 19% over the same period.

South Africa’s TB epidemic continues to be closely intertwined with HIV. Of the 235 000 people who fell ill with TB in 2025, an estimated 139 000 were living with HIV, and of the 53 000 TB deaths, just over half (27 000) were in people with HIV.

There were an estimated 14 000 cases of drug-resistant TB in the country in 2025.

The numbers in context

The new WHO TB incidence estimates are substantially lower than estimates from Thembisa, the leading mathematical model of HIV and TB in South Africa. According to Thembisa, an estimated 306 000 people aged 15 and older fell ill with TB in South Africa in 2025. The mortality figures are much closer though, with Thembisa also estimating 53 000 TB deaths in 2025 (although its estimate is only for people aged 15 and older).

The WHO and Thembisa estimates of the number of people who died of TB in 2025 are both more than double the numbers reported by Statistics South Africa (just under 19 000 in 2024). This difference is not unexpected since the WHO and Thembisa produced model estimates, while Stats SA’s mortality figures are essentially just a count of what is indicated on death notifications. There is good evidence showing that certain conditions are systematically under-reported on death notifications in South Africa.

A further nuance is that the WHO’s headline figure of 235 000 people falling ill with TB refers only to people who fell ill with TB in 2025. Many people who first fell ill with TB in 2024 would still have been ill with TB in 2025, and thus the total number of people who were ill with TB in 2025 is substantially higher than 235 000.

‘Missing cases’

Much has been made in recent years, including by Spotlight, about the many people who fall ill with TB who are not diagnosed or diagnosed late, a group sometimes referred to as the ‘missing cases’.

The number of people diagnosed with TB every year in South Africa has generally hovered at around 200 000. But while that number has been relatively stable, the WHO’s estimates of the actual number of TB cases have declined from over 300 000 to the current 235 000. If these estimates are accurate, then the number of ‘missing cases’ is only around 35 000, a far distance from the estimates of over 100 000 just five or so years ago.

It would be premature however to conclude that non-diagnosis or late diagnosis is no longer a problem in our TB response. First, the WHO itself is clear that its 235 000 estimate is very uncertain – their 95% uncertainty interval places the real number in the range from 148 000 to 342 000. It is also worth keeping in mind Thembisa’s much higher estimate of 306 000 people 15 and older falling ill with TB in 2025. And second, there is much good evidence showing that people with TB symptoms in South Africa are often not diagnosed, or diagnosed late.

According to a recent modelling study, a major gap in South Africa’s TB response is that many people who present at South Africa’s public sector clinics with TB symptoms are not offered TB tests. The classic symptoms of TB include persistent cough, night sweats, fatigue, chest pain, fever, and unexplained weight loss. The modelling suggests that simply testing more of the people presenting with these symptoms is one of the most effective things we can do in the fight against TB.

The bigger picture

Globally, an estimated 10.6 million people fell ill with TB in 2025 and 1.1 million people died from TB. Of the 10.6 million, only 8.4 million were diagnosed, leaving an estimated 2.2 million either undiagnosed or unreported, according to the WHO.

“The continued decline in TB cases and deaths is very encouraging, especially given the challenges many countries have faced from funding cuts,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General, in a media statement. “Many governments have dug deeper into their own budgets to protect the gains they have made. And yet, more than one million people still die each year from a disease that is preventable and treatable. We urge countries and partners to urgently expand access to TB services, protect essential funding and accelerate the development of new tools to end this epidemic.”

“With deaths falling by 35% since 2015 and treatment saving an estimated 86 million lives since 2000, the world has reached the first mortality milestone of WHO’s End TB Strategy, although five years later than planned. And progress has come too slowly,” the WHO said in its media release. “Since 2015, the global TB incidence rate (new cases per 100 000 population) has declined by 14%, far short of the 50% reduction milestone for 2025, and TB remains the leading cause of death from a single infectious agent.”

*This article was first published by Spotlight – health journalism in the public interest. Sign up to the Spotlight newsletter.

Antibiotics, Vaccinations and Anti-inflammatory Medication Linked to Reduced Risk of Dementia

Photo by cottonbro studio

Antibiotics, antivirals, vaccinations and anti-inflammatory medication are associated with reduced risk of dementia, according to new research that looked at health data from over 130 million individuals.

We urgently need new treatments to slow the progress of dementia, if not to prevent it. If we can find drugs that are already licensed for other conditions, then we can get them into trials much faster than we could do for an entirely new drug

Ben Underwood

The study, led by researchers from the universities of Cambridge and Exeter, identified several drugs already licensed and in use that have the potential to be repurposed to treat dementia.

Dementia is a leading cause of death in the UK and can lead to profound distress in the individual and among those caring for them. It has been estimated to have a worldwide economic cost in excess of US$1 trillion dollars.

Despite intensive efforts, progress in identifying drugs that can slow or even prevent dementia has been disappointing. Until recently, dementia drugs were effective only for symptoms and have a modest effect. Recently, lecanemab and donanemab have been shown to reduce the build-up in the brain of amyloid plaques – a key characteristic of Alzheimer’s disease – and to slow down progression of the disease, but the National Institute for Health and Care Excellence (NICE) concluded that the benefits were insufficient to justify approval for use within the NHS.

Scientists are increasingly turning to existing drugs to see if they may be repurposed to treat dementia. As the safety profile of these drugs is already known, the move to clinical trials can be accelerated significantly.  

Dr Ben Underwood, from the Department of Psychiatry at the University of Cambridge and Cambridgeshire and Peterborough NHS Foundation Trust, said: “We urgently need new treatments to slow the progress of dementia, if not to prevent it. If we can find drugs that are already licensed for other conditions, then we can get them into trials and – crucially – may be able to make them available to patients much, much faster than we could do for an entirely new drug. The fact they are already available is likely to reduce cost and therefore make them more likely to be approved for use in the NHS.”

In a study published today in Alzheimer’s and Dementia: Translational Research & Clinical Interventions, Dr Underwood, together with Dr Ilianna Lourida from the University of Exeter, led a systematic review of existing scientific literature to look for evidence of prescription drugs that altered the risk of dementia. Systematic reviews allow researchers to pool several studies where evidence may be weak, or even contradictory, to arrive at more robust conclusions.

In total, the team examined 14 studies that used large clinical datasets and medical records, capturing data from more than 130 million individuals and 1 million dementia cases. Although they found a lack of consistency between studies in identifying individual drugs that affect the risk of dementia, they identified several drug classes associated with altered risk.

One unexpected finding was an association between antibiotics, antivirals and vaccines, and a reduced risk of dementia. This finding supports the hypothesis that common dementias may be triggered by viral or bacterial infections, and supports recent interest in vaccines, such as the BCG vaccine for tuberculosis, and decreased risk of dementia.

Anti-inflammatory drugs such as ibuprofen were also found to be associated with reduced risk. Inflammation is increasingly being seen to be a significant contributor to a wide range of diseases, and its role in dementia is supported by the fact that some genes that increase the risk of dementia are part of inflammatory pathways.

The team found conflicting evidence for several classes of drugs, with some blood pressure medications and anti-depressants and, to a lesser extent, diabetes medication associated with a decreased risk of dementia and others associated with increased risk.

Dr Ilianna Lourida from the National Institute for Health and Care Research Applied Research Collaboration South West Peninsula (PenARC), University of Exeter, said: “Because a particular drug is associated with an altered risk of dementia, it doesn’t necessarily mean that it causes or indeed helps in dementia. We know that diabetes increases your risk of dementia, for example, so anyone on medication to manage their glucose levels would naturally also be at a higher risk of dementia – but that doesn’t mean the drug increases your risk.

“It’s important to remember that all drugs have benefits and risks. You should never change your medicine without discussing this first with your doctor, and you should speak to them if you have any concerns.”

The conflicting evidence may also reflect differences in how particular studies were conducted and how data was collected, as well as the fact that different medications even within the same class often target different biological mechanisms.

The UK government is supporting the development of an Alzheimer’s trial platform to evaluate drugs rapidly and efficiently, including repurposed drugs currently used for other conditions.

“Pooling these massive health data sets provides one source of evidence which we can use to help us focus on which drugs we should try first,” said Dr Underwood. “We’re hopeful this will mean we can find some much-needed new treatments for dementia and speed up the process of getting them to patients.”

Reference
Underwood, BU & Lourida, I et al. Data-driven discovery of associations between prescribed drugs and dementia risk: A systematic review. Alz & Dem; 21 Jan 2025; DOI: 10.1002/trc2.70037


Creative Commons License.
Republished from the d under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. 

Source: The University of Cambridge

16th November 2026: It’s Doctors’ Day!

Doctors’ Day is a significant occasion that holds immense importance in recognising and appreciating the dedication and tireless efforts of healthcare professionals who play a pivotal role in safeguarding and improving the well-being of individuals and communities. 

EthiQal proudly celebrates Doctors’ Day as a heartfelt tribute to the unwavering commitment of doctors to the noble cause of healing and saving lives. This day serves as an opportunity to express gratitude for the expertise, compassion, and sacrifices that doctors make in the service of humanity. 

We recognise the crucial role that doctors play in maintaining and promoting the highest standards of ethical medical practice. By celebrating Doctors’ Day, EthiQal not only honours the individual accomplishments of physicians but also underscores the collective impact of their work in advancing healthcare and fostering a culture of excellence in medical care.

What is and how is Doctors’ Day celebrated in South Africa?

Doctors’ Day in South Africa is celebrated annually on 16 November. It is a special day dedicated to recognising, honouring and thanking doctors for their commitment, compassion, expertise and contribution to the health and wellbeing of South Africans.

What is the significance of Doctors’ Day?

National Doctors’ Day was established in November 2018 through an initiative led by EthiQal, a medical professional indemnity provider.

The purpose is to:

  • Recognise the vital role doctors play in society.
  • Celebrate their dedication, knowledge and achievements.
  • Acknowledge the sacrifices and challenges they face.
  • Show appreciation for doctors working in both public and private healthcare.
  • Encourage South Africa to value and retain its medical professionals.

The initiative also highlights that doctors are a valuable national asset whose contribution deserves recognition and protection. 

BP Medications Linked to Fewer Complications in Ulcerative Colitis Treatment

Credit: Pixabay CC0

A class of blood-pressure medications may improve a widely used treatment for ulcerative colitis, the most common type of inflammatory bowel disease, according to a study led by Northwestern Medicine and Kiel University of thousands of patients.

The study found that those taking the blood-pressure meds for hypertension alongside vedolizumab (Entyvio) were less likely to experience serious complications resulting in hospitalisation and surgery to remove the colon. The findings were published in Nature Medicine.

Most patients with ulcerative colitis do not achieve lasting remission with available treatments, including advanced therapies such as vedolizumab.

“You’re talking about teens or young adults who are suffering from uncontrollable diarrhoea, bloody stool and an inability to function at school, work, or go out and have normal social interactions,” said Dr Parambir Dulai, associate professor of medicine at Northwestern University Feinberg School of Medicine. “And the psychosocial and physical impact of the disease is substantial, to the point where it may be on par with cancer in terms of the impact. Finding a new pathway where we have the potential to repurpose an inexpensive, generic, readily available medication could offer a tremendous reprieve for a lot of these young adults who are suffering on a daily basis.”

Dr Dulai, Dr Stefan Schreiber of Kiel University and colleagues analysed data from more than 1,300 patients in two clinical trials of vedolizumab for ulcerative colitis. By tracking symptom changes (stool frequency and rectal bleeding), they identified different response patterns.

Tissue biopsies and blood samples then showed that poor response was linked to vascular inflammation in the colon involving a pathway already targeted by ACE inhibitors and angiotensin-receptor blockers (ARBs).

Analysis of healthcare data from nearly 9000 ulcerative colitis patients with hypertension confirmed that, among those on vedolizumab, ACE-inhibitor or ARB use was associated with lower rates of hospitalisation or surgery. Other antihypertensive classes showed no such association, and the benefit was specific to vedolizumab.

Clinical trials are now needed to confirm the findings and to explore applicability in patients with normal blood pressure. “We don’t know yet if you can use anti-hypertensive medications in normal-tensive patients. People who have normal blood pressure, you don’t want to give them a medicine to drop their blood pressure,” said Dr Dulai. “There may be other ways to target that same pathway without the other effects that are present from blood pressure medications. In other words, our study offers a rationale to start thinking about developing drugs specifically for this.”

The team is also developing a diagnostic test based on the markers identified in non-responders, which could allow earlier identification of patients likely to respond or better suited to alternatives.

Source: Northwestern University

‘Living Medicine’ Tackles Drug-resistant Biofilms Growing on Ventilation Tubes

Scanning electron microscope images of the inner surface of breathing tubes in an infected pig showing the thick bacterial film that builds up on surface of ventilator tubes. Credit: Laia Fernández Barat and Kasra Kiarostami /Hospital Clínic-IDIBAPS

A ‘living medicine’ has thinned biofilms of antibiotic-resistant Pseudomonas aeruginosa in the lungs of pigs, according to the findings of a study published in the journal eBioMedicine.

The experimental treatment involves inhaling a genetically modified bacterium designed to target layers of drug-resistant P. aeruginosa that grow on the surfaces of endotracheal tubes used in hospitals.

It’s the first time the experimental treatment, which has previously only been shown to tackle biofilms in mice, has also worked in pigs, a large animal with lungs that are similar in size, structure and immune response to human lungs.

It’s also the first time the treatment has been shown to be administrable through a nebuliser, the same type of medical device human patients would use. Breathing in the “living medicine” thinned the biofilm inside breathing tubes from 6.08 to 3.67 micrometres, reducing thickness by around 40%.

The treatment involves Mycoplasma pneumoniae, a bacterium which normally causes a mild lung infection but, through genetic engineering, has been repurposed to be harmless for humans. The engineered bacterium was loaded with genes that dissolve sugars holding a biofilm together, as well as toxins that specifically only target Pseudomonas aeruginosa.

“Our study is part of an emerging field of medicine known as live biotherapeutics. In this case we’ve taken a bacterium naturally adapted to the lung and reprogrammed it so that it delivers therapeutic molecules instead of causing damage. It’s a Trojan horse strategy against disease,” explains Dr Irene Rodríguez-Arce, senior co-author of the study.

When examining the lungs afterwards, there were no signs of damage caused by the engineered bacterium. The treatment also showed no measurable effect on the animals’ own airway bacteria, suggesting the living medicine targets Pseudomonas specifically.

The study could one day help patients who cannot breathe for themselves in hospital. They are usually kept alive by passing a tube into the windpipe. Within days, bacteria colonise the inside of that tube and form a slimy, protective layer called a biofilm.

Antibiotics given through a drip struggle to penetrate the physical barrier of biofilms, causing recurring infections. In intubated patients, this is a known cause of ventilator-associated pneumonia (VAP). Around 1 in 4 cases are caused by Pseudomonas aeruginosa, which is frequently resistant to several types of antibiotics.

“Antibiotic resistance is a silent pandemic we see affecting intubated patients every day and Pseudomonas aeruginosa is among the hardest infections to clear,” says Laia Fernández Barat, first author of the study. “Our work represents a different line of attack, and one we badly need,” adds Dr Antoni Torres, senior co-author of the study.

The authors say their findings support a future first-in-human safety trial. Combining the “living medicine” with intravenous antibiotics or making further tweaks to the molecules that dissolve biofilms could further improve the experimental treatment’s effectiveness.

“I am confident that with modifications to the bacterial chassis’ payload, we could completely dissolve the biofilms on the surface of endotracheal tubes and clear P. aeruginosa infections entirely,” explains ICREA Research Professor Luis Serrano, senior co-author of the study.

The research team at the CRG are also creating versions of the living medicine that can tackle pulmonary fibrosis and lung cancer.

The study is a collaboration between the Centre for Genomic Regulation (CRG) and Hospital Clínic-IDIBAPS, both in Barcelona, with the animal studies carried out at the University of Barcelona. It was led by co-first authors Laia Fernández-Barat and Ana Motos, with Antoni Torres, Luis Serrano and Irene Rodríguez-Arce as senior authors. The study is funded by the “la Caixa” Foundation and the European Research Council.

10.1016/j.ebiom.2026.106537

Source: Centre for Genomic Regulation

Potential MND Therapy Restores Neuron Communication in the Lab

Photo by Louis Reed on Unsplash

A novel potential treatment approach for motor neuron disease (MND), similar to the approach being pursued with an investigational drug that recently entered human clinical trials, has been shown to restore broken communication between neurons in lab models of the disease. This could have beneficial therapeutic implications for 97% of people with MND, for whom there is currently no significant disease-modifying treatment.

Findings from a new study published in Nature, co-authored by researchers from King’s College London, University College London (UCL) and the Francis Crick Institute, along with Leibniz-FMP and Trace Neuroscience, pinpointed a single error in a key gene involved in MND that causes communication between neurons to break down, and used a drug to restore it in human neurons in the lab.

MND/ALS is a devastating and ultimately fatal disease that causes progressive muscle weakness due to the degeneration of motor neurons in the brain and spinal cord. As the disease advances, patients gradually lose the ability to move, speak, swallow and breathe. It is estimated to affect 1 in 300 people in their lifetime and there is no cure.

Currently, there are approved and experimental treatments for two rare genetic forms of ALS, which account for under 3% of cases. There is no significant disease-modifying treatment available for the remaining 97%. All of these cases share one feature: a key protein called TDP-43 stops doing its job correctly.

Normally, this protein is a proofreader for genetic material. Without this proofreading protein, neurons cannot process genetic material correctly, resulting in faulty proteins that are unable to carry out their normal roles.

By recreating in the lab what happens in human neurons when TDP-43 fails, researchers were able to see the knock-on effects of losing this proofreading protein on how neurons function. They found that without proper proofreading, there were errors in production of another key protein called UNC13A that normally lets neurons send signals to each other. Common genetic variants in UNC13A are already among the strongest known risk factors for MND.

The study found that a single error in how UNC13A is produced drastically reduced neuron communication. The researchers designed a type of drug, called an antisense oligonucleotide (ASO) to specifically target this error and were able to restore production of functional UNC13A protein, letting the neurons communicate again.

Another ASO that targets UNC13A dysfunction through a similar mechanism is already in clinical development in humans in the UK, Europe and China. Last month, the first UK participants were dosed with TRCN-1023 in Trace Neuroscience’s Phase 1/2 FUNCTION ALS clinical trial. UCL is a participating trial site.

We were surprised to see that restoring just one genetic event, out of the hundreds disrupted, was enough to allow neurons to talk to each other again.

Professor Juan Burrone, Professor of Developmental Neurophysiology, Institute of Psychiatry, Psychology & Neuroscience at King’s College London.

Professor Pietro Fratta, Professor of Cellular and Molecular Neuroscience at UCL and Group Leader at the Francis Crick Institute said:

“Our previous work told us UNC13A is important in ALS progression, but we still did not know in which way and to what extent it plays a role. We have now learned it’s the main driver of synaptic release deficits upon TDP-43 dysfunction, and have developed very effective antisense oligonucleotides to rescue this deficit. Excitingly these drugs have already entered clinical trials.”

Dr Rachel Jackson, one of the first authors on the paper, who carried out the research while she was a Research Associate at King’s, said:

“I used a live imaging technique that allowed me to see neurons signalling to each other under the microscope. Using this method, I saw that neurons with a change that mimics MND communicated less than neurons without the change.”

Source: King’s College London

Jolting Awake Often is Associated with Poorer Sleep and Higher Anxiety, Survey Finds

An online survey of 194 adults in Austria and Germany compared those who startle awake at least weekly with those who never or only rarely do.

Photo by Andrea Piacquadio

People who frequently startle awake while falling asleep – a phenomenon researchers call ‘sleep starts’ or hypnic jerks – report poorer sleep quality, greater insomnia severity, and higher anxiety than those who do not, according to a new study published this week in the open-access journal PLOS Mental Health by Tanja Grünberger and Manuel Schabus of Paris Lodron University Salzburg, Austria, and colleagues.

Sleep starts are sudden jolts that occur in the moments between wakefulness and sleep, most often felt as an abrupt muscle jerk or twitch, sometimes strong enough to jolt a person fully awake. The experience can also involve a sudden sensation of falling or loss of balance, electric-shock-like feelings, tingling or numbness, flashes of light, or brief, dream-like imagery. These experiences are frequently accompanied by a rush of emotion – alarm, confusion, fear, or panic – and physical signs of a startle response, such as a racing heart or rapid breathing. Afterward, most people fall back asleep quickly.

In the new study, researchers conducted an online survey of 194 adults in Austria and Germany who answered questions about their sleep quality, insomnia severity, daytime sleepiness, dysfunctional sleep-related beliefs, and symptoms of anxiety and depression. 96 of the participants experienced abrupt awakenings and at least one other symptom weekly, while the other 98 were used as a control group.

Compared with the control group, the sleep-starts group reported poorer sleep quality, greater insomnia severity, more dysfunctional sleep-related beliefs, and higher anxiety and depressive symptoms than those in the control group (all statistically significant). How often people experienced sleep starts was also linked to sleep quality, sleep beliefs, and anxiety, but not depression. Together, these factors, along with age and gender, were associated with about a quarter of the differences between people in sleep start frequency (26.9%). Participants also reported more frequent sleep starts during periods of psychological stress and emotional strain, whereas sleep deprivation was less influential on the frequency of sleep starts.

“These findings support the view that sleep starts should be considered within broader frameworks of sleep-related hyperarousal and cognitive-emotional activation,” the authors write. “Although causality cannot be inferred from these cross-sectional self-report data, the results highlight potentially relevant links between sleep starts and sleep-related cognitive-emotional processes.”

“These findings support the view that sleep starts should be considered within broader frameworks of sleep-related hyperarousal and cognitive-emotional activation,” the authors write. “Although causality cannot be inferred from these cross-sectional self-report data, the results highlight potentially relevant links between sleep starts and sleep-related cognitive-emotional processes.” First author Tanja Grünberger says: “Because there is no established questionnaire for sleep starts, we developed our own items based on the clinical literature. This allowed us to capture a broad range of experiences – but it also means that our findings now need to be confirmed with validated instruments and objective sleep recordings.” 

Dr Grünberger adds: “Sleep starts are much more than a simple muscle twitch when falling asleep. Participants described not only jerks, but also sensations of falling, a racing heart, flashes of light or loud bangs, and strong feelings of alarm or fear – and those who reported sleep starts at least once a week also reported poorer sleep quality, more unhelpful beliefs about sleep and more anxiety symptoms.”

She continues: “What we found most interesting was how closely sleep starts are linked to how people think and feel about sleep. The more strongly participants held unhelpful beliefs about sleep and the more anxious they were, the more often they reported sleep starts – and in the moment itself, many described a strong pressure to finally fall asleep. Our data cannot show what causes what, but this pattern resembles what we know from insomnia.”

 Senior author Manuel Schabus explains prospective next steps for their research: “For most people, sleep starts are a harmless feature of falling asleep. For a subgroup, however, they go along with distress and a longer time to fall asleep. Whether approaches that reduce arousal and sleep-related worry also help with distressing sleep starts has not yet been tested – that is an important next step.”

Provided by PLOS